Oxomemazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Oxomemazine is a phenothiazine derivative antihistamine indicated in the treatment of allergies.

Generic Name
Oxomemazine
DrugBank Accession Number
DB13820
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 330.45
Monoisotopic: 330.14019913
Chemical Formula
C18H22N2O2S
Synonyms
  • Oxomemazine

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination for symptomatic treatment ofColdCombination Product in combination with: Guaifenesin (DB00874)••• ••••••••
Used in combination for symptomatic treatment ofCoughingCombination Product in combination with: Guaifenesin (DB00874)••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Oxomemazine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
DroxidopaThe therapeutic efficacy of Droxidopa can be increased when used in combination with Oxomemazine.
EphedrineThe therapeutic efficacy of Ephedrine can be increased when used in combination with Oxomemazine.
EpinephrineThe therapeutic efficacy of Epinephrine can be increased when used in combination with Oxomemazine.
LevonordefrinThe therapeutic efficacy of Levonordefrin can be increased when used in combination with Oxomemazine.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be increased when used in combination with Oxomemazine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
R06AD08 — Oxomemazine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Benzenoids / 1,4-thiazines / Sulfones / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Alkyldiarylamine / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
305MB38V1C
CAS number
3689-50-7
InChI Key
QTQPVLDZQVPLGV-UHFFFAOYSA-N
InChI
InChI=1S/C18H22N2O2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)23(21,22)18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
IUPAC Name
10-[3-(dimethylamino)-2-methylpropyl]-10H-5lambda6-phenothiazine-5,5-dione
SMILES
CC(CN(C)C)CN1C2=CC=CC=C2S(=O)(=O)C2=CC=CC=C12

References

General References
Not Available
Human Metabolome Database
HMDB0240230
ChemSpider
18281
ChEBI
135408
ChEMBL
CHEMBL2104734
Wikipedia
Oxomemazine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCough1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SyrupOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0856 mg/mLALOGPS
logP2.81ALOGPS
logP3.18Chemaxon
logS-3.6ALOGPS
pKa (Strongest Basic)8.02Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area40.62 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity94.22 m3·mol-1Chemaxon
Polarizability35.83 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0k96-9772000000-3ec457a1ac6a72f2456b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0209000000-8230848c8ef487a57a15
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0039000000-855e2c0b130dafa40436
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-05ai-9344000000-996e94a9bcf109bdf527
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0039000000-4ffe12048840a05a1fe9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000x-0390000000-e7fd87cff10e9c35e20c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0bu0-4090000000-234eaa5e5cc6176c4072
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-188.531346
predicted
DarkChem Lite v0.1.0
[M-H]-169.9164
predicted
DeepCCS 1.0 (2019)
[M+H]+189.254346
predicted
DarkChem Lite v0.1.0
[M+H]+172.27438
predicted
DeepCCS 1.0 (2019)
[M+Na]+188.869146
predicted
DarkChem Lite v0.1.0
[M+Na]+178.36754
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:49 / Updated at May 21, 2021 10:23